Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluating in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn.SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.
聖地亞哥，2024年11月25日（全球新聞網絡）—— kura oncology, Inc.（納斯達克：KURA）是一家臨床階段的生物製藥公司，致力於實現精準醫學在癌症治療中的承諾，今天宣佈參與即將舉行的 JMP Securities 血液學和腫瘤學峯會。Troy Wilson, Ph.D., J.D.，總裁兼首席執行官，定於2024年12月2日下午2:00（東部時間）/上午11:00（太平洋時間）參加一次虛擬爐邊聊天。
A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at , with an archived replay available following the live event.
爐邊聊天的現場音頻網絡廣播將在 Kura 的網站投資者部分提供，直播活動結束後會有檔案重播。
About Kura Oncology
關於kura oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluating in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn.
Kura Oncology是一家臨床階段的生物製藥公司，致力於實現精準醫學在癌症治療中的承諾。公司的管道包括針對癌症信號通路的小分子藥物候選者。Ziftomenib是一種每日一次口服的menin抑制劑，是首個也是唯一一個獲得美國食品和藥物管理局（FDA）突破性治療認定的研究療法，旨在治療復發/難治性（R/R）NPM1突變急性髓性白血病（AML）。2024年11月，Kura與共立株式會社達成了一項全球戰略合作協議，以開發和商業化ziftomenib用於急性髓性白血病和其他血液惡性腫瘤。在復發/難治性NPM1突變急性髓性白血病的ziftomenib II期註冊指導試驗中已完成入組，雙方預計將在2025年提交新藥申請。Kura還在進行一系列臨床試驗，以評估ziftomenib與新診斷和復發/難治性NPM1突變和KMT2A重排急性髓性白血病的標準治療的聯合應用。KO-2806，一種下一代法尼酰轉移酶抑制劑，正在進行I期劑量遞增試驗，作爲單藥療法和與靶向治療的組合。Tipifarnib，一種強效且選擇性FTI，目前正在與alpelisib聯合進行I/II期試驗，適用於PIK3CA依賴的頭頸部鱗狀細胞癌。有關更多信息，請訪問Kura的網站，並在X和LinkedIn上關注我們。
Kura Contacts
kura oncology 聯繫人
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
投資者:
Pete De Spain
執行副總裁，投資者關係
企業通訊
858-500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
媒體:
Cassidy McClain
副總裁
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
譯文內容由第三人軟體翻譯。
